Table 2 Malignant lesions on core needle biopsy.
Feature | Number (%) | |
|---|---|---|
Invasive carcinoma | 164 | |
Histologic type | ||
Microinvasive (not typed) | 3 (2%) | |
No special type (“ductal”) | 63 (38%) | |
Mixed ductal and lobular | 31 (19%) | |
Lobular | 53 (32%) | |
Tubulolobular | 2 (1%) | |
Tubular | 12 (7%) | |
Grade | ||
Microinvasive (not graded) | 3 (2%) | |
1 | 98 (60%) | |
2 | 59 (36%) | |
3 | 4 (2%) | |
Estrogen receptor | ||
Positive | 160 (98%) | |
Negative | 4 (2%) | |
Progesterone receptor | ||
Positive | 134 (82%) | |
Negative | 29 (18%) | |
HER2 | ||
Positive | 3 (2%) | |
Negative | 161 (98%) | |
Biologic type | ||
Luminal-like (ER+/HER2−) | 158 (96%) | |
Luminal/HER2-like (ER+/HER2+) | 2 (1%) | |
HER2-like (ER−/PR-/HER2+) | 1 (1%) | |
Basal-like (ER−/PR−/HER2−) | 3 (2%) | |
T classification (after excision) (n = 129):a | No special type (“ductal”) (n = 54) | Lobular or mixed ductal and lobular (n = 75) |
|---|---|---|
T1a (>0.1–0.5 cm) | 9 (17%) | 4 (5%) |
T1b (>0.5–1.0 cm) | 15 (28%) | 16 (21%) |
T1c (>1.0–2.0 cm) | 26 (48%) | 34 (45%) |
T2 (>2.0–5.0 cm) | 3 (6%) | 20 (27%) |
T3 (>5.0 cm) | 1 (2%) | 1 (1%) |
Lymph nodes (n = 119)b | ||
N0 | 97 (82%) | |
N1 | 15 (13%) | |
N2 | 4 (3%) | |
N3 | 3 (3%) | |
AJCC Pathologic Prognostic Stage Group (n = 114)c | ||
I | 105 (92%) (91 IA, 14 IB) | |
II | 2 (2%) | |
III | 5 (4%) | |
IV | 2 (2%) | |
Ductal carcinoma in situ | 20 | |
Nuclear grade | ||
1 | 1 (5%) | |
2 | 11 (55%) | |
3 | 8 (40%) | |
Necrosis | ||
Present | 12 (60%) | |
Absent | 8 (40%) | |
Calcifications | ||
Present | 16 (80%) | |
Absent | 4 (20%) | |
Estrogen receptor | ||
Positive | 18 (90%) | |
Negative | 2 (10%) | |
Extent | ||
Average no. of blocks | 12 | |
Range | 4–38 | |
Associated lesion | ||
Sclerosing | 13 (65%) | |
Papilloma | 1 (5%) | |
None | 6 (30%) | |
